Relevance to other NICE programmes

Relevance to other NICE programmes

This use of liraglutide (Saxenda) is being considered for referral for a NICE technology appraisal. At the time of publication of this evidence summary a technology appraisal was not considered appropriate due to the intention of the manufacturers to only promote the use of liraglutide (Saxenda) on private prescription. The manufacturers have indicated that they do not intend to promote the use of liraglutide (Saxenda) within the NHS. This evidence summary does not contain recommendations from NICE on whether the medicine should be prescribed within the NHS or by private prescription.

NICE has issued guidelines on:

A NICE technology appraisal on the use of naltrexone-bupropion prolonged release (European Public Assessment Report: Mysimba) for weight management in people who are obese or overweight with associated risk factors is in development with an expected publication date of August 2017.

NICE has also issued guidance on the use of liraglutide for type 2 diabetes: